SCIENTURE Announces Third Patent Grant for ARBLI™ (Losartan Potassium) Oral Suspension, Strengthening Long-Term Market Exclusivity Through 2041

Why It Matters

The extended patent life secures a high‑margin niche in a large hypertension market, giving Scienture a defensible advantage over compounding alternatives and potential generic entrants.

Key Takeaways

• Third USPTO patent secures ARBLI exclusivity until Oct 2041
• First FDA‑approved liquid losartan targets 72 M annual prescriptions
• Liquid formulation eliminates compounding, boosting adherence for pediatric/geriatric patients
• $241 M U.S. losartan market offers sizable revenue opportunity
• Scienture aims to expand formulary access and physician awareness

Pulse Analysis

The third patent awarded to ARBLI™ marks a strategic win for Scienture, cementing a 15‑year exclusivity window that outlasts most small‑molecule lifecycles. By covering novel liquid formulations and specific methods of use, the patent shields the product from generic competition and from potential infringement claims tied to compounding practices. This robust IP portfolio not only protects revenue streams but also enhances the company’s valuation, a critical factor as it seeks additional capital for broader market rollout.

Hypertension remains a pervasive health challenge, with roughly half of U.S. adults—about 120 million people—requiring treatment. Losartan, an angiotensin receptor blocker, accounts for a $241 million market and 72 million prescriptions each year. However, a sizable subset of patients, including children, the elderly, and those with swallowing difficulties, cannot reliably use tablet forms. ARBLI™’s ready‑to‑use, peppermint‑flavored suspension eliminates the need for pharmacy compounding, delivering consistent dosing, longer shelf life, and room‑temperature storage. These attributes directly address adherence gaps that drive costly hospitalizations and suboptimal blood‑pressure control.

From a commercial perspective, Scienture is leveraging the patent shield to accelerate formulary placement and physician education. The company’s strategy includes expanding distribution through specialty pharmacies, targeting health‑system contracts, and highlighting the clinical benefits of a liquid ARB in peer‑reviewed forums. As insurers increasingly prioritize medication adherence metrics, ARBLI™ could qualify for favorable reimbursement tiers, further boosting uptake. Looking ahead, the extended exclusivity through 2041 provides a runway for potential line extensions—such as fixed‑dose combinations or pediatric‑specific concentrations—allowing Scienture to deepen its foothold in the antihypertensive space while delivering measurable value to patients and payers.